Free Trial
NASDAQ:LIXT

Lixte Biotechnology (LIXT) Stock Price, News & Analysis

Lixte Biotechnology logo
$3.97 -0.25 (-5.92%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$3.94 -0.03 (-0.63%)
As of 07/11/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lixte Biotechnology Stock (NASDAQ:LIXT)

Key Stats

Today's Range
$3.62
$4.45
50-Day Range
$0.71
$4.22
52-Week Range
$0.64
$4.45
Volume
830,867 shs
Average Volume
679,572 shs
Market Capitalization
$10.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Lixte Biotechnology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
7th Percentile Overall Score

LIXT MarketRank™: 

Lixte Biotechnology scored higher than 7% of companies evaluated by MarketBeat, and ranked 848th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Lixte Biotechnology.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lixte Biotechnology is -2.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lixte Biotechnology is -2.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Lixte Biotechnology's valuation and earnings.
  • Percentage of Shares Shorted

    8.49% of the float of Lixte Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Lixte Biotechnology has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lixte Biotechnology has recently increased by 4,146.67%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Lixte Biotechnology does not currently pay a dividend.

  • Dividend Growth

    Lixte Biotechnology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.49% of the float of Lixte Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Lixte Biotechnology has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lixte Biotechnology has recently increased by 4,146.67%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Lixte Biotechnology has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Lixte Biotechnology this week, compared to 0 articles on an average week.
  • Search Interest

    3 people have searched for LIXT on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Lixte Biotechnology to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lixte Biotechnology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    14.80% of the stock of Lixte Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 5.10% of the stock of Lixte Biotechnology is held by institutions.

  • Read more about Lixte Biotechnology's insider trading history.
Receive LIXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lixte Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

LIXT Stock News Headlines

This Cold War “Accident” Could Unleash New $100 Trillion AI Boom
Obscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.
See More Headlines

LIXT Stock Analysis - Frequently Asked Questions

Lixte Biotechnology's stock was trading at $2.03 at the beginning of 2025. Since then, LIXT stock has increased by 95.6% and is now trading at $3.97.

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) issued its quarterly earnings data on Monday, May, 12th. The company reported ($0.29) earnings per share for the quarter.

Shares of Lixte Biotechnology reverse split before market open on Monday, June 5th 2023.The 1-10 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Lixte Biotechnology (LIXT) raised $7 million in an initial public offering (IPO) on Wednesday, November 25th 2020. The company issued 1,500,000 shares at $4.75 per share. WestPark Capital and WallachBeth Capital served as the underwriters for the IPO.

Shares of LIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lixte Biotechnology investors own include Predictive Oncology (POAI), Sangamo Therapeutics (SGMO), Ford Motor (F), Insulet (PODD), Energy Select Sector SPDR Fund (XLE), Zomedica (ZOM) and Abbott Laboratories (ABT).

Company Calendar

Last Earnings
5/12/2025
Today
7/12/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LIXT
CIK
1335105
Employees
4
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.45)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.59 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-189.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.26
Quick Ratio
4.26

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.19) per share
Price / Book
-3.34

Miscellaneous

Outstanding Shares
2,680,000
Free Float
2,287,000
Market Cap
$10.64 million
Optionable
Not Optionable
Beta
0.31
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:LIXT) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners